StreetAlpha.app
Home › Stocks › DCTH

Delcath Systems, Inc. (DCTH)

$19.37
▼ −2.52%
LAST CLOSE · NOV 17

Delcath is a medical company that makes the HEPZATO KIT and CHEMOSAT for treating cancers in the liver. It last closed at $19.37 on Nov 17, down 2.52% on the day. The average 12-month price target from 2 analysts is $30.50 (+57.5% from the last close), with a high of $36.00 and a low of $25.00.

AI Auto Pilots
Is DCTH in one of our four AI portfolios? Sign in free to see

Key Stats

Last 12 months
Results
Revenue
$110.0M
+38.1% vs a year ago
Net income
$6.7M
+455.4% vs a year ago
EPS (diluted)
$0.16
+433.3% vs a year ago
Free cash flow
$20.1M
18.3% margin
Valuation
Market cap
$673.8M
34.8M shares
P/E
121.1
Price over 12 month EPS
Price to sales
6.1
Market cap over revenue
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$55.5M
At Sep 30
Shareholder equity
$133.5M
Buybacks
$9.0M
Last 12 months
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: $3.6M$3.6MFY2021FY2022: $2.7M$2.7MFY2022FY2023: $2.1M$2.1MFY2023FY2024: $37.2M$37.2MFY2024FY2025: $85.2M$85.2MFY2025

From DCTH's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 9). Last 12 months adds up the four latest quarters.

Last report
Nov 9
2026 · next date not on the calendar yet
Consensus EPS forecast
—
 
Year-ago EPS
—
Not on file
Options-implied move
—
 
Analyst consensus
2 Buy
2 firms · not enough for a consensus
Loading…

Analyst Ratings & Price Targets

Analyst Ratings →
Ratings · 90 days
2 Buy
2firms
2 Buy0 Hold0 Sell
Only 2 firms rated DCTH in the past 90 days, not enough for a consensus
Average 12-month target
$30.50
▲ 57.5% upside

Based on 2 analysts who set a price target on DCTH in the past 90 days. The average target is $30.50, with a high of $36.00 and a low of $25.00, compared with the last close of $19.37.

Low $25.00Avg $30.50High $36.00
Blue marker: last close $19.37
Highest target$36.00
Average target$30.50
Lowest target$25.00
Latest rating changes
BTIGReiterated
Nov 12Buy$25
HC Wainwright & Co.Target raised
Nov 10Buy$32 → $36
BTIGTarget raised
Nov 9Buy$21 → $25
HC Wainwright & Co.Maintained
Aug 7Buy$32
BTIGMaintained
Aug 6Buy$21
DateFirmActionRatingPrice target
Nov 12BTIGReiteratedBuy$25
Nov 10HC Wainwright & Co.Target raisedBuy$32 → $36
Nov 9BTIGTarget raisedBuy$21 → $25
Aug 7HC Wainwright & Co.MaintainedBuy$32
Aug 6BTIGMaintainedBuy$21
Loading…

Technical Analysis

DCTH · as of the Nov 17 close · updated after every close
Uptrend, nearing overbought

The stock is 14% above its 20 day and 17% above its 50 day average. It is 34% above its 200 day average, so the longer trend is still up. Momentum is strong (RSI 63), near overbought. The nearest support is the Pivot S1 at $19.13, and the nearest resistance the Pivot at $19.57.

Short trendBullish
Long trendBullish
MomentumStrong
StretchNear overbought
VolatilityHigh, 5.6%/day
Key levels
$22.5152 week high+16.2%
$22.51Swing high (Nov 12)+16.2%
$19.81Pivot R1+2.3%
$19.57Pivot+1.0%
$19.37Last close
$19.13Pivot S1−1.2%
$16.6520 day average−14.0%
$16.51Swing low (Aug 17)−14.8%
$16.0250 day average−17.3%
$15.27100 day average−21.2%
$12.81200 day average−33.9%
$8.1252 week low−58.1%
Indicators
RSI (14)62.89Strong, overbought above 70Neutral
MACD1.40Above its signal lineBullish
Stochastic70.0Middle of its rangeNeutral
ADX (14)34.9Trending up
Williams %R-36.5Oversold below −80, overbought above −20Neutral
CCI (20)72.3Oversold below −100, overbought above 100Neutral
Rate of change+34.5%Change over 10 sessionsBullish
ATR (14)$1.09Typical daily range, 5.6% of price
MA 10Above
MA 20Above
MA 50Above
MA 100Above
MA 200Above
What happened before, for DCTH

What happened before

See how DCTH did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.

November seasonalityHow DCTH usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

Seasonality

How DCTH has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2018.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D

No whale options trades in DCTH in the last 90 days.

Loading…

See today’s whale options flow across the market →

DCTH Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Strongly bullish
Strongly bearishNeutralStrongly bullish
  • ▲90 buying vs 46 selling
  • ▲Held by funds +9.5 pts
  • ▲Funds holding +23
  • ▲Superinvestors: 3 added, 0 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding145122+18.9%
In funds' top 10220.0%
Held by funds59.6%50.1%+9.5 pts
New / increased36 / 5420 / 48+32.4%
Reduced / sold out33 / 1325 / 20+2.2%
Put/call ratio0.000.82−100.0%
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See DCTH institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

AI Auto Pilots

Paper trading

StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether DCTH is in one of them and how their past DCTH trades turned out.

DCTH in the AI portfolios
Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered DCTH in an article yet. Here's the latest on the wider market.

DCTH Congress Trades

All congress trades →
Trades, 12 months
0
Buys
0
Sells
0
People
0
Last filed Aug 6
Who traded DCTH · since 2017
Latest 1 filing
$1K – $15KTraded Jun 9, 2017Filed Aug 6, 2018
PersonTypeAmountTradedFiledDelay
Roger MarshallR · KSSell$1K – $15KJun 9, 2017Aug 6, 2018423 d

Members of Congress and senior officials report trades up to 45 days later, as dollar ranges. Filings show a trade happened, not why. Not investment advice.

About Delcath Systems

Delcath is a medical company focused on treating cancers that have spread to the liver or started there. Its lead product is the HEPZATO KIT, a combined drug and device treatment approved in the United States for adults with uveal melanoma that has spread to the liver. In Europe, Delcath sells CHEMOSAT, a device used at medical centers to deliver treatment to the liver. Its treatments are performed by interventional radiologists, and the company is based in Queensbury, New York.

Headquarters
Queensbury, NY
Founded
1988